Dr. Robinson, in 2010, co-founded and was CEO of Tactic Pharma. He helped lead Tactic through a successful sale of its lead compound. His passion is leveraging his interests in medicine, science, and finance to help bring new therapeutics to patients. The compound Dr. Robinson researched at Northwestern University as an undergraduate, and published on in Science, is currently in a Phase III clinical trial for Wilson Disease. Among his previous experiences, Dr. Robinson in 2008 worked at Onyx Pharmaceuticals in their Nexavar marketing division, from 2008-2009 as a co-manager of a healthcare clinic in San Jose CA, from 2004 to present as Founder and President of an undergraduate research focused non-profit, and from 2006 to 2007 at Bear Stearns investment bank. He was previously on the board of Wilson Therapeutics (acquired by Alexion), and is currently on the board of Northwestern University's Chemistry of Life Processes Institute. Dr. Robinson graduated summa cum laude from Northwestern University, earned a master's degree in International Health Policy and Health Economics from the London School of Economics on a Fulbright Scholarship, an MBA from Cambridge University on a Gates Scholarship, and an MD from Stanford University.

Dr. Starr has helped bring 6 orphan product drugs to market, and as co-founder and CEO of Raptor Pharmaceuticals (recently purchased by Horizon Pharma), oversaw the approval, launch, and successful commercialization of Procysbi®. He served as Raptor’s initial CEO since its inception in 2006 through 2014 and continued to serve on Raptor’s board of directors until Raptor was sold to Horizon Pharma in October 2016. Dr. Starr co-founded BioMarin Pharmaceutical Inc. in 1997 where he last served as Senior Vice President and Chief Scientific Officer until starting Raptor in 2006. As Senior Vice President at BioMarin, Dr. Starr was responsible for managing a Scientific Operations team of 181 research, process development, manufacturing and quality personnel through the successful development of commercial manufacturing processes for its enzyme replacement and small molecule products, and supervised the cGMP design, construction and licensing of BioMarin's proprietary biological manufacturing facility. From 1991 to 1998, Dr. Starr supervised research and commercial programs at BioMarin's predecessor company, Glyko, Inc., where he served as Vice President of Research and Development. Prior to his tenure at Glyko, Inc., Dr. Starr was a National Research Council Associate at the National Institutes of Health. Dr. Starr earned a B.S. from Syracuse University and a Ph.D. in Biochemistry and Molecular Biology from the State University of New York Health Science Center, in Syracuse, New York.

Mr. Cittadine is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization to acquisition by Fortune Global 1000 firms. These include founding two successful diagnostic imaging companies, and leading both through acquisitions by Siemens and Olympus. His leadership experience also includes acting as startup CEO of critical care company which was acquired by Medtronic. He has managed manufacturing and quality systems implementation, execution of multi-center clinical trials, and regulatory clearances for new technologies in Europe and the US. Mr. Cittadine received his BA, BS, and MS from Stanford and an MBA from Northwestern’s Kellogg School of Management. 

Mr. Vu brings over 20 years of corporate and financial strategy, investment banking and public company experience.  From October 2024 through February 2025, Mr. Vu served as a Venture Partner of ZhongMei Capital, an investment firm focused on early-stage biopharmaceutical companies. In 2023 he served as Chief Financial Officer and Chief Business Officer of Ocugen, Inc. (NASDAQ: OCGN) and prior to that, he served as Chief Operating Officer and Chief Business Officer for 180 Life Sciences Corp. (NASDAQ: ATNF) from November 2021 to January 2023. Before joining 180 Life Sciences and since 2019, Mr. Vu has provided services as a consultant/independent contractor through his own consulting firm, Melius BioPharma Consulting. Under Melius, he has served in various capacities for the following companies: 1) LS Associates, a life science services firm and a member company of LifeSci Partners, as an interim C-suite consultant since July 2020; 2) Baleena Bioscience, Inc., a biomedical company focused on healthspan, as CEO from April 2021 through October 2021; and 3) Solganick & Co., a technology investment banking firm, as Managing Director and Co-Head of Healthcare IT, from September 2019 through October 2021 and again from August 2024 through February 2025. From September 2016 to August 2019, Mr. Vu served as Vice President and Head of Strategy and Corporate & Business Development at Opiant Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company acquired by Indivior PLC (LSE: INDV.L). Prior to Opiant, he held leadership roles of increasing responsibility at Impax Laboratories, Inc., Elevance Health, Inc. (formerly Anthem, Inc.) and Amgen, Inc. Earlier in his career, he worked in the healthcare corporate finance and M&A departments at bulge-bracket investment banks, including Morgan Stanley and Goldman Sachs. Mr. Vu obtained his MS in Legal Studies from Cornell University Law School and BA in Economics from UCLA, graduating summa cum laude with College Honors and Economics Departmental Honors. He is also a Certified Treasury Professional (inactive).

Previously Chief Medical Officer of Raptor Pharmaceutical, Ferrokin Biosciences and Edison Pharmaceuticals. At Raptor, Dr. Rioux handled Clinical and Regulatory Affairs, Clinical Pharmacology, Clinical Operations, Medical Affairs, Pharmacovigilance, submitted NDA (FDA) and MAA (EMA) at the same time and got approval one year later, one month apart in the US and the EU. Therapeutic expertise includes early development Phase 1 - 2 in metabolic diseases, CNS (neurology, psychiatry and pain management), immunology and oncology. Dr. Rioux received his Medical Education at Faculté de Médecine-Salpêtrière, his PhD in Mathematical Statistics at Faculté des Sciences, and his Degree of Pharmacology (pharmacokinetics and clinical pharmacology) at Faculté de Médecine-Salpêtrière.

Mr. Anderson has more than 30 years of biopharmaceutical sector experience, primarily focused in financial management. He was CFO at such notable companies as BioMarin and Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International), and was a board member and chair of the audit committee for Raptor Pharmaceutical Corp. (now a wholly owned subsidiary of Horizon Pharma plc).

Mr. Klausner has been a consultant to the biopharmaceutical industry since 2009 and currently serves as Executive Chairman of Concarlo Therapeutics, Inc. From 2018 to 2022, he served as President, Chief Executive Officer, and a Director of the start-up drug development company Goldilocks Therapeutics, Inc. He served as CEO of Gem Pharmaceuticals, LLC (“Gem”) from 2012 until Gem’s drug development assets were acquired by Monopar in 2017. In addition, he was CEO of Jade Therapeutics Inc. from 2012 to 2015. Previously, Mr. Klausner spent a total of 18 years at the life science venture capital firms Domain Associates and Pappas Ventures, where he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies.

Ms. Tsuchimoto was Monopar’s first Chief Financial Officer, having served as a consultant from June 2015 to October 2017, then as an employee from November 2017 until her retirement in June 2024. She has spent over nine years at Raptor Pharmaceuticals, as its Chief Financial Officer from Raptor’s inception in May 2006 until August 2012, as Raptor’s Vice President of International Finance, Tax & Treasury from September 2012 to February 2015, and lastly served as Raptor’s Vice President, Financial Planning & Analysis and Internal Controls from February to May 2015. At Raptor, Ms. Tsuchimoto completed: two reverse mergers, one to initially trade on the OTCBB, the second to gain Raptor’s Nasdaq listing; over $100 million of financings (primarily equity); one clinical asset purchase; and one clinical platform asset license, which later became Raptor’s first commercial product and lead program. Ms. Tsuchimoto has drafted numerous SEC mandated reports such as 10-Ks, 10-Qs, Form 4s, S-1s, S-3s and prospectus supplements. Prior to Raptor, Ms. Tsuchimoto spent eight years at BioMarin Pharmaceutical Inc. and its predecessor, Glyko, Inc., where she held the positions of Vice President-Treasurer, Vice President-Controller and Controller. At BioMarin, Ms. Tsuchimoto provided due diligence for the company’s IPO in 1999 and helped close BioMarin’s first $500 million of financing between 1997 and 2005. Ms. Tsuchimoto was responsible for BioMarin’s SEC reporting, corporate compliance, 10(b)5-1 trading plans and was BioMarin’s primary liaison with external legal counsel and auditors in the company’s early years. Prior to Glyko, she served as Controller at a few companies outside the biotech industry. She began her career as a staff accountant in a local certified public accounting firm. Ms. Tsuchimoto received a B.S. in Business Administration from San Francisco State University. She holds an inactive California Certified Public Accountant license.

Ms. Talukdar has served as Senior Vice President, Head of Investor Relations at Moderna Inc. since April 2019. She brings over 20 years of experience in investor relations, healthcare investments, and financial strategy. Before joining Moderna, Ms. Talukdar was a Senior Portfolio Manager at Abu Dhabi Investment Authority (ADIA), overseeing global healthcare investments, and previously served as a Partner and Healthcare Equity Analyst at Lord Abbett & Co. She also held investment roles at MFS Investment Management and State Street Global Advisors. Ms. Talukdar received her B.S. in Business Administration from SUNY Stony Brook and is a CFA charterholder.